Top

31-10-2024 | Pediatric Endocrinology and Diabetology | Review Article Free for a limited time

Clinical utility of anti-Müllerian hormone in female children and adolescents

Authors: Effrosyni Birbas, Anastasia Vatopoulou, Theofilos Kanavos, Kyriakos Birmpas, Chara Skentou, Athanasios Zikopoulos, Fani Gkrozou

Published in: Hormones

Abstract

Anti-Müllerian hormone (AMH) is a dimeric glycoprotein that belongs to the transforming growth factor beta superfamily and plays essential roles in sexual differentiation and folliculogenesis. In the male embryo, AMH is produced by the Sertoli cells and induces the involution of the Müllerian ducts. In females, AMH is predominately produced by the granulosa cells of growing preantral and small antral follicles and regulates follicular maturation. Many recent studies have highlighted the significant role of this hormone in the diagnostic approach to female children and adolescents with various disorders that affect ovarian development and function. AMH is considered a valuable diagnostic tool in the management of female pediatric patients with conditions such as polycystic ovary syndrome, precocious puberty, ovarian tumors, differences in sex development, and premature ovarian insufficiency. Standardization of AMH assays, internationally approved reference values based on age and pubertal stage, and widespread availability of the test could further upgrade the clinical utility of AMH, rendering it a valuable tool in the armamentarium of physicians involved in the care of female children and adolescents, and promote future research.

Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C, Mason H, Nelson SM, Visser JA, Wallace WH, Anderson RA (2014) The physiology and clinical utility of anti-mullerian hormone in women. Hum Reprod Update 20:370–385. https://doi.org/10.1093/humupd/dmt062CrossRefPubMed

Iwase A, Hasegawa Y, Tsukui Y, Kobayashi M, Hiraishi H, Nakazato T, Kitahara Y (2023) Anti-Müllerian hormone beyond an ovarian reserve marker: the relationship with the physiology and pathology in the life-long follicle development. Front Endocrinol (Lausanne) 14:1273966. https://doi.org/10.3389/fendo.2023.1273966CrossRefPubMed

Leader B, Baker VL (2014) Maximizing the clinical utility of antimüllerian hormone testing in women’s health. Curr Opin Obstet Gynecol 26:226–236. https://doi.org/10.1097/GCO.0000000000000087CrossRefPubMed

Zhao F, Grimm SA, Jia S, Yao HH-C (2022) Contribution of the wolffian duct mesenchyme to the formation of the female reproductive tract. PNAS Nexus 1:pgac182. https://doi.org/10.1093/pnasnexus/pgac182CrossRefPubMed

Grinspon RP, Rey RA (2010) Anti-müllerian hormone and sertoli cell function in paediatric male hypogonadism. Horm Res Paediatr 73:81–92. https://doi.org/10.1159/000277140CrossRefPubMed

Russell N, Gilmore A, Roudebush WE (2022) Clinical utilities of Anti-Müllerian hormone. J Clin Med 11:7209. https://doi.org/10.3390/jcm11237209CrossRefPubMed

van der Kooi A-LLF, van den Heuvel-Eibrink MM, van den Berg SAA, van Dorp W, Pluijm SMF, Laven JSE (2019) Changes in Anti-Müllerian hormone and inhibin B in children treated for Cancer. J Adolesc Young Adult Oncol 8:281–290. https://doi.org/10.1089/jayao.2018.0130CrossRefPubMed

Kanakatti Shankar R, Dowlut-McElroy T, Dauber A, Gomez-Lobo V (2022) Clinical utility of anti-mullerian hormone in Pediatrics. J Clin Endocrinol Metab 107:309–323. https://doi.org/10.1210/clinem/dgab687CrossRefPubMed

Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP (1999) Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 140:5789–5796. https://doi.org/10.1210/endo.140.12.7204CrossRefPubMed

10.

Lunsford AJ, Whelan K, McCormick K, McLaren JF (2014) Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors. Fertil Steril 101:227–231. https://doi.org/10.1016/j.fertnstert.2013.08.052CrossRefPubMed

11.

Asanidze E, Kristesashvili J, Parunashvili N, Karelishvili N, Etsadashvili N (2021) Challenges in diagnosis of polycystic ovary syndrome in adolescence. Gynecol Endocrinol 37:819–822. https://doi.org/10.1080/09513590.2021.1943344CrossRefPubMed

12.

Dursun F, Güven A, Yıldız M (2016) Assessment of Anti-Müllerian hormone level in management of adolescents with polycystic ovary syndrome. J Clin Res Pediatr Endocrinol 8:55–60. https://doi.org/10.4274/jcrpe.2338CrossRefPubMed

13.

Yetim A, Yetim Ç, Baş F, Erol OB, Çığ G, Uçar A, Darendeliler F (2016) Anti-Müllerian hormone and Inhibin-A, but not Inhibin-B or insulin-like Peptide-3, may be used as surrogates in the diagnosis of polycystic ovary syndrome in adolescents: preliminary results. J Clin Res Pediatr Endocrinol 8:288–297. https://doi.org/10.4274/jcrpe.3253CrossRefPubMed

14.

Jopling H, Yates A, Burgoyne N, Hayden K, Chaloner C, Tetlow L (2018) Paediatric Anti-Müllerian hormone measurement: male and female reference intervals established using the automated Beckman Coulter Access AMH assay. Endocrinol Diabetes Metab 1:e00021. https://doi.org/10.1002/edm2.21CrossRefPubMed

15.

Yates AP, Jopling HM, Burgoyne NJ, Hayden K, Chaloner CM, Tetlow L (2019) Paediatric reference intervals for plasma anti-Müllerian hormone: comparison of data from the Roche Elecsys assay and the Beckman Coulter Access assay using the same cohort of samples. Ann Clin Biochem 56:536–547. https://doi.org/10.1177/0004563219830733CrossRefPubMed

16.

Ronn R, Bohn MK, Greenblatt EM, Hoffman B, Adeli K (2022) Anti-mullerian hormone (AMH) reference values in the CALIPER cohort of healthy community children and adolescents. Clin Biochem 108:63–66. https://doi.org/10.1016/j.clinbiochem.2022.06.005CrossRefPubMed

17.

NCD Risk Factor Collaboration (NCD-RisC) (2017) Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 390:2627–2642. https://doi.org/10.1016/S0140-6736(17)32129-3CrossRef

18.

Czech I, Partyka M, Drosdzol-Cop A (2023) Does body mass index affect anti-mullerian hormone levels in girls and adolescents? Ginekol Pol. https://doi.org/10.5603/GP.a2023.0013

19.

Tsukui Y, Kitahara Y, Hasegawa Y, Kobayashi M, Osuka S, Iwase A (2022) Anti-Müllerian hormone levels in the diagnosis of adolescent polycystic ovarian syndrome: a systematic review and meta-analysis. Endocr J 69:897–906. https://doi.org/10.1507/endocrj.EJ22-0081CrossRefPubMed

20.

Simpson S, Seifer DB, Shabanova V, Lynn AY, Howe C, Rowe E, Caprio S, Vash-Margita A (2020) The association between anti-Müllerian hormone and vitamin 25(OH)D serum levels and polycystic ovarian syndrome in adolescent females. Reprod Biol Endocrinol 18:118. https://doi.org/10.1186/s12958-020-00676-yCrossRefPubMed

21.

Kim JY, Tfayli H, Michaliszyn SF, Lee S, Nasr A, Arslanian S (2017) Anti-Müllerian hormone in obese adolescent girls with polycystic ovary syndrome. J Adolesc Health 60:333–339. https://doi.org/10.1016/j.jadohealth.2016.10.015CrossRefPubMed

22.

Hart R, Doherty DA, Norman RJ, Franks S, Dickinson JE, Hickey M, Sloboda DM (2010) Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Fertil Steril 94:1118–1121. https://doi.org/10.1016/j.fertnstert.2009.11.002CrossRefPubMed

23.

Ran Y, Yi Q, Li C (2021) The relationship of anti-mullerian hormone in polycystic ovary syndrome patients with different subgroups. Diabetes Metab Syndr Obes 14:1419–1424. https://doi.org/10.2147/DMSO.S299558CrossRefPubMed

24.

Chen T, Wu H, Xie R, Wang F, Chen X, Sun H, Chen L (2017) Serum Anti-Müllerian hormone and inhibin B as potential markers for progressive central precocious puberty in girls. J Pediatr Adolesc Gynecol 30:362–366. https://doi.org/10.1016/j.jpag.2017.01.010CrossRefPubMed

25.

Sahin NM, Kinik ST, Tekindal MA, Bayraktar N (2015) AMH levels at central precocious puberty and premature thelarche: is it a parameter? J Pediatr Endocrinol Metab 28:1351–1356. https://doi.org/10.1515/jpem-2014-0521CrossRefPubMed

26.

Efthymiadou A, Bogiatzidou M, Kritikou D, Chrysis D (2019) Anti-Müllerian hormone in girls with premature Adrenarche: the impact of polycystic ovary syndrome history in their mothers. J Pediatr 205:190–194. https://doi.org/10.1016/j.jpeds.2018.09.064CrossRefPubMed

27.

Muratoğlu Şahin N, Bayramoğlu E, Nursun Özcan H, Kurnaz E, Keskin M, Savaş-Erdeve Ş, Çetinkaya S, Aycan Z (2019) Antimüllerian hormone levels of infants with premature Thelarche. J Clin Res Pediatr Endocrinol 11:287–292. https://doi.org/10.4274/jcrpe.galenos.2019.2018.0293CrossRefPubMed

28.

Rey RA, Belville C, Nihoul-Fékété C, Michel-Calemard L, Forest MG, Lahlou N, Jaubert F, Mowszowicz I, David M, Saka N, Bouvattier C, Bertrand AM, Lecointre C, Soskin S, Cabrol S, Crosnier H, Léger J, Lortat-Jacob S, Nicolino M, Rabl W, Toledo SP, Baş F, Gompel A, Czernichow P, Josso N (1999) Evaluation of gonadal function in 107 intersex patients by means of serum antimüllerian hormone measurement. J Clin Endocrinol Metab 84:627–631. https://doi.org/10.1210/jcem.84.2.5507CrossRefPubMed

29.

Josso N, Belville C, di Clemente N, Picard J-Y (2005) AMH and AMH receptor defects in persistent Müllerian duct syndrome. Hum Reprod Update 11:351–356. https://doi.org/10.1093/humupd/dmi014CrossRefPubMed

30.

Stuchi-Perez EG, Hackel C, Oliveira LEC, Ferraz LFC, Oliveira LC, Nunes-Silva D, Toralles MB, Steinmetz L, Damiani D, Maciel-Guerra AT, Guerra-Junior G (2005) Diagnosis of 5alpha-reductase type 2 deficiency: contribution of anti-Müllerian hormone evaluation. J Pediatr Endocrinol Metab 18:1383–1389. https://doi.org/10.1515/jpem.2005.18.12.1383CrossRefPubMed

31.

Rey R, Mebarki F, Forest MG, Mowszowicz I, Cate RL, Morel Y, Chaussain JL, Josso N (1994) Anti-müllerian hormone in children with androgen insensitivity. J Clin Endocrinol Metab 79:960–964. https://doi.org/10.1210/jcem.79.4.7962305CrossRefPubMed

32.

Liu Q, Yin X, Li P (2020) Clinical, hormonal and genetic characteristics of androgen insensitivity syndrome in 39 Chinese patients. Reprod Biol Endocrinol 18:34. https://doi.org/10.1186/s12958-020-00593-0CrossRefPubMed

33.

Chen S, Yang B, Fan J (2020) Diagnostic value of anti-mullerian hormone in ovarian granulosa cell tumor: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 253:266–272. https://doi.org/10.1016/j.ejogrb.2020.08.011CrossRefPubMed

34.

Kitajima M, Kajimura I, Kitajima Y, Murakami N, Matsumura A, Matsumoto K, Harada A, Hasegawa Y, Miura K (2023) AMH producing purely cystic virilizing adult granulosa cell tumor in 17 years old girl: a case report and review of literatures. J Ovarian Res 16:52. https://doi.org/10.1186/s13048-023-01134-0CrossRefPubMedPubMedCentral

35.

De Sanctis V, Ahmed S, Soliman A, Alyafei F, Alaaraj N, Al Maadheed M, Clelland C (2021) A rare case of ovarian juvenile Granulosa Cell Tumor in an infant with Isosexual Pseudo Puberty and a revision of literature. Acta Biomed 92:e2021319. https://doi.org/10.23750/abm.v92i4.11572CrossRefPubMedPubMedCentral

36.

George SA, Williamson Lewis R, Schirmer DA, Effinger KE, Spencer JB, Mertens AC, Meacham LR (2019) Early detection of ovarian dysfunction by anti-mullerian hormone in adolescent and young adult-aged survivors of Childhood Cancer. J Adolesc Young Adult Oncol 8:18–25. https://doi.org/10.1089/jayao.2018.0080CrossRefPubMed

37.

Anderson RA, Cameron D, Clatot F, Demeestere I, Lambertini M, Nelson SM, Peccatori F (2022) Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. Hum Reprod Update 28:417–434. https://doi.org/10.1093/humupd/dmac004CrossRefPubMedPubMedCentral

38.

Wang J, Lan T, Dai X, Yang L, Hu X, Yao H (2023) The Cut-Off Value of Serum Anti-Müllerian Hormone Levels for the Diagnosis of Turner Syndrome with Spontaneous Puberty. Int J Endocrinol 2023:6976389. https://doi.org/10.1155/2023/6976389

39.

Visser JA, Hokken-Koelega ACS, Zandwijken GRJ, Limacher A, Ranke MB, Flück CE (2013) Anti-Müllerian hormone levels in girls and adolescents with Turner syndrome are related to karyotype, pubertal development and growth hormone treatment. Hum Reprod 28:1899–1907. https://doi.org/10.1093/humrep/det089CrossRefPubMed

40.

Hamza RT, Mira MF, Hamed AI, Ezzat T, Sallam MT (2018) Anti-Müllerian hormone levels in patients with turner syndrome: relation to karyotype, spontaneous puberty, and replacement therapy. Am J Med Genet A 176:1929–1934. https://doi.org/10.1002/ajmg.a.40473CrossRefPubMed

41.

Lunding SA, Aksglaede L, Anderson RA, Main KM, Juul A, Hagen CP, Pedersen AT (2015) AMH as Predictor of premature ovarian insufficiency: a longitudinal study of 120 Turner Syndrome patients. J Clin Endocrinol Metab 100:E1030–1038. https://doi.org/10.1210/jc.2015-1621CrossRefPubMed

42.

Bustamante VH, Galetaki DM, Dowlut-McElroy T, Kanakatti Shankar R (2023) Anti-mullerian hormone and spontaneous puberty in a diverse US Turner syndrome clinic cohort: a cross-sectional study. Clin Endocrinol (Oxf). https://doi.org/10.1111/cen.14971CrossRefPubMed

43.

Codner E, Iñiguez G, Hernández IM, Lopez P, Rhumie HK, Villarroel C, Rey RA (2011) Elevated anti-Müllerian hormone (AMH) and inhibin B levels in prepubertal girls with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 74:73–78. https://doi.org/10.1111/j.1365-2265.2010.03887.xCrossRefPubMed

44.

Bouzas ICdaS, Cader SA, Leão L, Kuschnir MC, Braga C (2014) Menstrual cycle alterations during adolescence: early expression of metabolic syndrome and polycystic ovary syndrome. J Pediatr Adolesc Gynecol 27:335–341. https://doi.org/10.1016/j.jpag.2014.01.002CrossRefPubMed

45.

Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO, ESE PCOS Special Interest Group (2014) The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 171:P1–29. https://doi.org/10.1530/EJE-14-0253CrossRefPubMed

46.

Dumont A, Robin G, Catteau-Jonard S, Dewailly D (2015) Role of Anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review. Reprod Biol Endocrinol 13:137. https://doi.org/10.1186/s12958-015-0134-9CrossRefPubMed

47.

Hickey M, Sloboda DM, Atkinson HC, Doherty DA, Franks S, Norman RJ, Newnham JP, Hart R (2009) The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J Clin Endocrinol Metab 94:3714–3720. https://doi.org/10.1210/jc.2009-0544CrossRefPubMed

48.

Shrikhande L, Shrikhande B, Shrikhande A (2020) AMH and its clinical implications. J Obstet Gynaecol India 70:337–341. https://doi.org/10.1007/s13224-020-01362-0CrossRefPubMed

49.

Kocaay P, Siklar Z, Buyukfirat S, Berberoglu M (2018) The diagnostic value of Anti-Müllerian hormone in early Post Menarche adolescent girls with polycystic ovarian syndrome. J Pediatr Adolesc Gynecol 31:362–366. https://doi.org/10.1016/j.jpag.2018.02.126CrossRefPubMed

50.

Witchel SF, Oberfield S, Rosenfield RL, Codner E, Bonny A, Ibáñez L, Pena A, Horikawa R, Gomez-Lobo V, Joel D, Tfayli H, Arslanian S, Dabadghao P, Garcia Rudaz C, Lee PA (2015) The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr. https://doi.org/10.1159/000375530CrossRefPubMed

51.

Singh AK, Singh R (2015) Can anti-mullerian hormone replace ultrasonographic evaluation in polycystic ovary syndrome? A review of current progress. Indian J Endocrinol Metab 19:731–743. https://doi.org/10.4103/2230-8210.167548CrossRefPubMed

52.

Teede H, Misso M, Tassone EC, Dewailly D, Ng EH, Azziz R, Norman RJ, Andersen M, Franks S, Hoeger K, Hutchison S, Oberfield S, Shah D, Hohmann F, Ottey S, Dabadghao P, Laven JSE (2019) Anti-Müllerian hormone in PCOS: a Review Informing International guidelines. Trends Endocrinol Metab 30:467–478. https://doi.org/10.1016/j.tem.2019.04.006CrossRefPubMed

53.

Crisosto N, Codner E, Maliqueo M, Echiburú B, Sánchez F, Cassorla F, Sir-Petermann T (2007) Anti-Müllerian hormone levels in peripubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 92:2739–2743. https://doi.org/10.1210/jc.2007-0267CrossRefPubMed

54.

Farello G, Altieri C, Cutini M, Pozzobon G, Verrotti A (2019) Review of the literature on current changes in the timing of Pubertal Development and the incomplete forms of early puberty. Front Pediatr 7:147. https://doi.org/10.3389/fped.2019.00147CrossRefPubMed

55.

Teilmann G, Pedersen CB, Jensen TK, Skakkebaek NE, Juul A (2005) Prevalence and incidence of precocious pubertal development in Denmark: an epidemiologic study based on national registries. Pediatrics 116:1323–1328. https://doi.org/10.1542/peds.2005-0012CrossRefPubMed

56.

Lashen H, Dunger DB, Ness A, Ong KK (2013) Peripubertal changes in circulating antimüllerian hormone levels in girls. Fertil Steril 99:2071–2075. https://doi.org/10.1016/j.fertnstert.2013.01.139CrossRefPubMed

57.

Smith MB, Ho J, Ma L, Lee M, Czerwinski SA, Glenn TL, Cool DR, Gagneux P, Stanczyk FZ, McGinnis LK, Lindheim SR (2021) Longitudinal antimüllerian hormone and its correlation with pubertal milestones. F S Rep 2:238–244. https://doi.org/10.1016/j.xfre.2021.02.001CrossRefPubMed

58.

Jeong HR, Lee HJ, Shim YS, Kang MJ, Yang S, Hwang IT (2020) Inhibin B as a screening tool for early detection and treatment monitoring of central precocious puberty. Gynecol Endocrinol 36:768–771. https://doi.org/10.1080/09513590.2020.1718642CrossRefPubMed

59.

Savas-Erdeve S, Sagsak E, Keskin M, Cetinkaya S, Aycan Z (2017) AMH levels in girls with various pubertal problems. J Pediatr Endocrinol Metab 30:333–335. https://doi.org/10.1515/jpem-2016-0217CrossRefPubMed

60.

Hagen CP, Sørensen K, Anderson RA, Juul A (2012) Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist. Fertil Steril 98:1326–1330. https://doi.org/10.1016/j.fertnstert.2012.07.1118CrossRefPubMed

61.

Nam HK, Kim HR, Rhie YJ, Lee KH (2017) Serum Anti-Müllerian hormone levels in precocious puberty girls according to stage of GnRH agonist treatment. J Korean Med Sci 32:475–479. https://doi.org/10.3346/jkms.2017.32.3.475CrossRefPubMed

62.

Vuralli D, Ciftci N, Demirbilek H (2023) Serum kisspeptin, neurokinin B and inhibin B levels can be used as alternative parameters to distinguish idiopathic CPP from premature thelarche in the early stages of puberty. Clin Endocrinol (Oxf) 98:788–795. https://doi.org/10.1111/cen.14906CrossRefPubMed

63.

Allen NG, Krishna KB, Lee PA (2022) Differences of Sex Development: what neonatologists need to know. Clin Perinatol 49:207–218. https://doi.org/10.1016/j.clp.2021.11.013CrossRefPubMed

64.

Hughes IA (2008) Disorders of sex development: a new definition and classification. Best Pract Res Clin Endocrinol Metab 22:119–134. https://doi.org/10.1016/j.beem.2007.11.001CrossRefPubMed

65.

Guerrero-Fernández J, Azcona San Julián C, Barreiro Conde J, de la Bermúdez JA, Carcavilla Urquí A, Castaño González LA, Martos Tello JM, Rodríguez Estévez A, Yeste Fernández D, Martínez Martínez L, Martínez-Urrutia MJ, Mora Palma C, Audí, Parera L (2018) [Management guidelines for disorders / different sex development (DSD)]. An Pediatr (Engl Ed) 89:315.e1-315.e19. https://doi.org/10.1016/j.anpedi.2018.06.009

66.

Lamanna B, Vinciguerra M, Dellino M, Cascella G, Cazzato G, Macorano E, Malvasi A, Scacco S, Cicinelli E, Loizzi V, Vimercati A, Cormio G, Paduano F, Cascardi E, Tatullo M (2022) Turner Syndrome Mosaicism 45,X/46,XY with genital ambiguity and duchenne muscular dystrophy: Translational Approach of a rare Italian case. Int J Mol Sci 23:14408. https://doi.org/10.3390/ijms232214408CrossRefPubMed

67.

Josso N, Rey RA (2020) What does AMH tell us in Pediatric disorders of Sex Development? Front Endocrinol (Lausanne) 11:619. https://doi.org/10.3389/fendo.2020.00619CrossRefPubMed

68.

Lahlou N, Fennoy I, Carel J-C, Roger M (2004) Inhibin B and anti-Müllerian hormone, but not testosterone levels, are normal in infants with nonmosaic Klinefelter syndrome. J Clin Endocrinol Metab 89:1864–1868. https://doi.org/10.1210/jc.2003-031624CrossRefPubMed

69.

Syryn H, Van De Vijver K, Cools M (2023) Ovotesticular Difference of Sex Development: genetic background, histological features, and Clinical Management. Horm Res Paediatr 96:180–189. https://doi.org/10.1159/000519323CrossRefPubMed

70.

Lucas-Herald AK, Mitchell RT (2022) Testicular sertoli cell hormones in differences in Sex Development. Front Endocrinol (Lausanne) 13:919670. https://doi.org/10.3389/fendo.2022.919670CrossRefPubMed

71.

Picard J-Y, Cate RL, Racine C, Josso N (2017) The Persistent Müllerian Duct Syndrome: an update based upon a personal experience of 157 cases. Sex Dev 11:109–125. https://doi.org/10.1159/000475516CrossRefPubMed

72.

Henes M, Jurow L, Peter A, Schoenfisch B, Taran FA, Huebner M, Seeger H, Brucker SY, Rall KK (2018) Hyperandrogenemia and ovarian reserve in patients with Mayer-Rokitansky-Küster-Hauser syndrome type 1 and 2: potential influences on ovarian stimulation. Arch Gynecol Obstet 297:513–520. https://doi.org/10.1007/s00404-017-4596-1CrossRefPubMed

73.

Hughes LA, McKay-Bounford K, Webb EA, Dasani P, Clokie S, Chandran H, McCarthy L, Mohamed Z, Kirk JMW, Krone NP, Allen S, Cole TRP (2019) Next generation sequencing (NGS) to improve the diagnosis and management of patients with disorders of sex development (DSD). Endocr Connect 8:100–110. https://doi.org/10.1530/EC-18-0376CrossRefPubMed

74.

Sessa C, Schneider DT, Planchamp F, Baust K, Braicu EI, Concin N, Godzinski J, McCluggage WG, Orbach D, Pautier P, Peccatori FA, Morice P, Calaminus G (2020) ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers. Lancet Oncol 21:e360–e368. https://doi.org/10.1016/S1470-2045(20)30091-7CrossRefPubMed

75.

Birbas E, Kanavos T, Gkrozou F, Skentou C, Daniilidis A, Vatopoulou A (2023) Ovarian masses in children and adolescents: a review of the literature with emphasis on the Diagnostic Approach. Child (Basel) 10:1114. https://doi.org/10.3390/children10071114CrossRef

76.

Lindhardt Johansen M, Hagen CP, Johannsen TH, Main KM, Picard J-Y, Jørgensen A, Rajpert-De Meyts E, Juul A (2013) Anti-müllerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development. Int J Endocrinol 2013:198698. https://doi.org/10.1155/2013/198698CrossRefPubMed

77.

Hagen CP, Fischer MB, Mola G, Mikkelsen TB, Cleemann LH, Gravholt CH, Viuff MH, Juul A, Pedersen AT, Main KM (2023) AMH and other markers of ovarian function in patients with Turner syndrome - a single center experience of transition from pediatric to gynecological follow up. Front Endocrinol (Lausanne) 14:1173600. https://doi.org/10.3389/fendo.2023.1173600CrossRefPubMed

78.

Rodrigues Oliveira SM, Rebocho A, Ahmadpour E, Nissapatorn V, de Lourdes Pereira M (2023) Type 1 diabetes Mellitus: a review on advances and challenges in creating insulin producing devices. Micromachines (Basel) 14:151. https://doi.org/10.3390/mi14010151CrossRefPubMed

79.

Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, Bell R, Badaru A, Talton JW, Crume T, Liese AD, Merchant AT, Lawrence JM, Reynolds K, Dolan L, Liu LL, Hamman RF, SEARCH for Diabetes in Youth Study (2014) Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 311:1778–1786. https://doi.org/10.1001/jama.2014.3201CrossRefPubMedPubMedCentral

Title: Clinical utility of anti-Müllerian hormone in female children and adolescents
Authors: Effrosyni Birbas
Anastasia Vatopoulou
Theofilos Kanavos
Kyriakos Birmpas
Chara Skentou
Athanasios Zikopoulos
Fani Gkrozou
Publication date: 31-10-2024
Publisher: Springer International Publishing
Keywords: Pediatric Endocrinology and Diabetology
Disorder of Sex Development
Polycystic Ovary Syndrome
Primary Ovarian Insufficiency
Polycystic Ovary Syndrome
Puberty
Published in: Hormones
Print ISSN: 1109-3099
Electronic ISSN: 2520-8721
DOI: https://doi.org/10.1007/s42000-024-00603-5

At a glance: The STEP trials

Obesity
Clinical Trial Summary

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content

At a glance: The STEP trials